SE9903031D0 - Peptide mixture and vaccine against a chronic viral infection - Google Patents

Peptide mixture and vaccine against a chronic viral infection

Info

Publication number
SE9903031D0
SE9903031D0 SE9903031A SE9903031A SE9903031D0 SE 9903031 D0 SE9903031 D0 SE 9903031D0 SE 9903031 A SE9903031 A SE 9903031A SE 9903031 A SE9903031 A SE 9903031A SE 9903031 D0 SE9903031 D0 SE 9903031D0
Authority
SE
Sweden
Prior art keywords
hepatitis
peptide mixture
viral infection
vaccine against
mixture
Prior art date
Application number
SE9903031A
Other languages
Swedish (sv)
Inventor
Catharina Hultgren
Matti Saellberg
Original Assignee
Eurodiagnostica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodiagnostica Ab filed Critical Eurodiagnostica Ab
Priority to SE9903031A priority Critical patent/SE9903031D0/en
Publication of SE9903031D0 publication Critical patent/SE9903031D0/en
Priority to AU79031/00A priority patent/AU7903100A/en
Priority to JP2001519724A priority patent/JP2003508409A/en
Priority to EP00969241A priority patent/EP1206278A2/en
Priority to PCT/EP2000/008124 priority patent/WO2001016163A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is a peptide mixture, a pharmaceutical composition and a vaccine against a chronic infection caused by a virus comprising a mixture of 10 to 30 amino acids (aa) long peptides each with a 5 to 25 aa overlap of the adjacent overlapping peptide spanning the amino acid sequence of a viral protein of said virus, e.g. Hepatitis B, Hepatitis C, GBvirus-C, HIV and Herpes viruses. Hepatitis B has been used as an example and it is demonstrated that a peptide mixture composed of seventeen 20 to 23 aa long peptides spanning the amino acids 1 to 183 of the hepatitis B core antigen (HBcAg) could activate specific T cells regardless of the host MHC/HLA genotype that recognize the native protein processed by professional antigen presenting cells (APCs). Further, a method is described for the treatment of a viral infection, particularly a non-resolving chronic viral infection, making use of the novel peptide mixture immunogen.
SE9903031A 1999-08-27 1999-08-27 Peptide mixture and vaccine against a chronic viral infection SE9903031D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE9903031A SE9903031D0 (en) 1999-08-27 1999-08-27 Peptide mixture and vaccine against a chronic viral infection
AU79031/00A AU7903100A (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection
JP2001519724A JP2003508409A (en) 1999-08-27 2000-08-21 Peptide mixtures and vaccines against chronic viral infections
EP00969241A EP1206278A2 (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection
PCT/EP2000/008124 WO2001016163A2 (en) 1999-08-27 2000-08-21 Peptide mixture and vaccine against a chronic viral infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903031A SE9903031D0 (en) 1999-08-27 1999-08-27 Peptide mixture and vaccine against a chronic viral infection

Publications (1)

Publication Number Publication Date
SE9903031D0 true SE9903031D0 (en) 1999-08-27

Family

ID=20416772

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9903031A SE9903031D0 (en) 1999-08-27 1999-08-27 Peptide mixture and vaccine against a chronic viral infection

Country Status (5)

Country Link
EP (1) EP1206278A2 (en)
JP (1) JP2003508409A (en)
AU (1) AU7903100A (en)
SE (1) SE9903031D0 (en)
WO (1) WO2001016163A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique MIXTURE OF PEPTIDES FROM PAPILLOMAVIRUS E6 AND / OR E7 PROTEINS AND THEIR APPLICATIONS
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
NZ544011A (en) * 2003-06-10 2009-02-28 Univ Melbourne Immunomodulating compositions uses therefor and processes for their production
GB0608368D0 (en) * 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
DK2040745T3 (en) * 2006-06-28 2013-03-18 Statens Seruminstitut Expansion of the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide mixtures
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2185196B1 (en) 2007-08-27 2014-06-11 Longhorn Vaccines & Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP2106803A1 (en) 2008-04-04 2009-10-07 Fondazione Centro San Raffaele del Monte Tabor Method to design and uses of overlapping peptides for monitoring T-cell responses in HIV patients
CN102060929A (en) * 2010-06-07 2011-05-18 夏书奇 T-cell immune balance peptide
EP3079716B1 (en) * 2013-12-13 2019-05-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope tarp peptide vaccine and uses thereof
US20220257748A1 (en) * 2019-06-07 2022-08-18 Oregon Health & Science University Hepatitis b virus-specific t cell responses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9201139D0 (en) * 1992-01-20 1992-03-11 Connaught Lab Synthetic peptides for a rubella vaccine
ES2287969T3 (en) * 1992-03-06 2007-12-16 Innogenetics N.V. HIV PEPTIDES
WO1996022067A2 (en) * 1994-12-27 1996-07-25 United Biomedical, Inc. Peptide ratchet libraries for ctl-inducing vaccines and therapeutics

Also Published As

Publication number Publication date
WO2001016163A3 (en) 2001-09-07
EP1206278A2 (en) 2002-05-22
WO2001016163A2 (en) 2001-03-08
JP2003508409A (en) 2003-03-04
AU7903100A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
SE9903031D0 (en) Peptide mixture and vaccine against a chronic viral infection
AU771827B2 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
Wiktor et al. Antigenic properties of rabies virus components
DK11789A (en) RECOMBINANT VACCINIA VIRA
DK0596979T3 (en) Plant virus recombinant nucleic acids
ES2075440T3 (en) VACCINE AGAINST HEPATITIS B.
AU2007202739A1 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
NO167359C (en) PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST INFECTION OF HEPATITIS B VIRUS.
RU2319505C2 (en) Purified coat proteins of hepatitis c virus for diagnostic and therapeutic application
ATE134195T1 (en) PEPTIDE FRAGMENTS OF HIV
SE9202968D0 (en) NEW PEPTIDES, DIAGNOSTIC ANTIGENS, USE THEREOF, VACCINES AND MEDICAMENTS
AR009365A1 (en) FMD VIRUS VACCINES (FMDV), PEPTIDES, DNA SEQUENCES AND THE USE OF PEPTIDES IN DETECTION SYSTEMS AND THE USE OF FMDC VACCINE FOR PREPARATION OF A COMPOSITION TO IMMUNIZE PIGS AND CATTLE
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
KR950005326A (en) Recombinant Adenovirus Vaccine
Beauverger et al. Serotype-specific and canine distemper virus cross-reactive H-2Kk-restricted cytotoxic T lymphocyte epitopes in the measles virus nucleoprotein
EP0257721B1 (en) Vaccine
WO2007127290A3 (en) Method for producing viral vaccine and therapeutic peptide antigens
GB9925966D0 (en) Threapeutic vaccines against variable viruses and other targets
TR200202169T1 (en) Purified hepatitis C virus envelope proteins for use in diagnosis and treatment.
AU6839598A (en) Antigenic structural peptide, antigenic and immunogenic compounds and uses for detecting, preventing and treating an hcv infection
ES2163405T3 (en) RECOMBINANT VIRUSES UNDERSTANDING ARTIFICIAL PROTEOLITIC SCISION SITES.
RU94030478A (en) Recombinant virus, method of its preparing, immunization method, method of protein preparing, vaccine composition, use of recombinant virus
AU2004200155C1 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
TH4070EX (en) DNA sequence containing the code of P31 seraphase antigen, modified hepatitis B virus.
AU2006235980B9 (en) HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV